Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing <i>Enterobacterales</i> ?: a Systematic Review and Meta-analysis
Burcu Isler, Yukiko Ezure, José Luis García-Fogeda Romero, Patrick N. A. Harris, Adam G. Stewart, David L. Paterson
Abstract
Carbapenem-sparing regimens are needed for the treatment of infections caused by extended-spectrum-β-lactamase (ESBL)- and AmpC-producing members of the Enterobacterales . We sought to compare the clinical efficacy of ceftazidime/avibactam and carbapenems against ESBL- and AmpC-producing Enterobacterales species. A systematic review and meta-analysis of randomized controlled trials comparing ceftazidime/avibactam with carbapenems for the treatment of ESBL- and AmpC-producing Enterobacterales was conducted.
Topics & Concepts
Ceftazidime/avibactamCeftazidimeMedicineMeta-analysisCarbapenemIntensive care medicineCephalosporinAvibactamRandomized controlled trialMicrobiologyAntibioticsPseudomonas aeruginosaInternal medicineBiologyBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntibiotic Use and Resistance